Thursday, January 1, 2026 1/1/2026

Functional consequences of SMARCB1 variants

Award Number: R01CA289761
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2029

Group Awards By:

View Award Description

Functional consequences of SMARCB1 variants - ABSTRACT SMARCB1 deficient cancers constitute a growing number of rare and difficult to treat cancers affecting children, adolescents and young adults. Our clinical assessments of SMARCB1 function rely upon immunohistochemistry and thus our ability to determine nuances of SMARCB1 function remain limited. Unlike other better characterized tumor suppressors such as PTEN or TP53, SMARCB1 has been in the cancer biology literature since the 1990s. More recently, genetic variants of unknown significance in SMARCB1 have been identified across 1% of all cancers. Despite computational efforts to assign function, we know that members of the SWI/SNF chromatin remodeling complex such as SMARCB1 have been difficult to assess given the limited structural data available. To address this gap, we have performed deep mutagenesis scanning of SMARCB1 which enables the assessment of >99% of genetic mutations across SMARCB1. This proposal now focuses on understanding the mechanisms behind these genetic changes. Specifically, we will enhance our understanding of key mutations and residues that are important in SMARCB1’s ability to bind to other SWI/SNF complex members. We will understand how missense mutations in these key regions lead to oncogenic phenotypes. We will then study the effects of hyper-functional SMARCB1 missense mutants to further enhance our understanding of the biology of SMARCB1. Taken together, success of these aims will improve our understanding of these genetic variants of unknown significance as well as the biology of SMARCB1.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $470,970 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	2	12/15/2025	NON-COMPETING CONTINUATION	$470,970
														Subtotal = $470,970

Issue Date FY: 2025 ( Subtotal = $489,527 )
2025	2025	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	1	12/17/2024	NEW	$489,527
														Subtotal = $489,527

Grand Total All Awards = $960,497

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Functional consequences of SMARCB1 variants

Award Number: R01CA289761

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer